Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia

Breast Journal

Volumn 12, Issue SUPPL. 1, 2006, Pages

  Groot, Martijn T ^a   Baltussen, Rob ^a   Uyl De Groot, Carin A ^a   Anderson, Benjamin O ^b   Hortobágyi, Gabriel N ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Cost effectiveness; Costs; Developing countries; Economic evaluation; Modeling

Indexed keywords

AFRICA; ARTICLE; ASIA; BREAST CANCER; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; EARLY DIAGNOSIS; FATALITY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; NORTH AMERICA; OUTCOME ASSESSMENT; SIMULATION;

AFRICA; ASIA; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMETRIC; NEOPLASM STAGING; NORTH AMERICA; QUALITY-ADJUSTED LIFE YEARS;

EID: 33644910748     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2006.00206.x     Document Type: Article

References (33)

1. Stewart B Kleihues PE. World Cancer Report Lyon, France IARC Press 2003
2. Ferlay J Bray F Pisani P Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide [CD-ROM]. IARC CancerBase no. 5, version 2.0 Lyon, France IARC Press 2004
3. International Agency for Research on Cancer Working Group on the Evaluation of Cancer-Preventive Strategies. Handbooks of Cancer Prevention vol. 7 Breast Cancer Screening Lyon, France IARC Press 2002
4. World Health Organization. Fifty-eighth World Health Assembly, resolution WHA58.22, Cancer Prevention and Control Geneva, Switzerland World Health Organization May 25 2005
5. Radice D Redaelli A. Breast cancer management: quality-of-life and cost considerations Pharmacoeconomics 2003 21 383 96
6. Murray CJ Lauer JA Hutubessy RC et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Lancet 2003 361 717 25
7. Shibuya K Ciecierski C Guindon E Bettcher DW Evans DB Murray CJ. WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty BMJ 2003 327 154 57
8. Dziekan G Chisholm D Johns B Rovira J Hutin YJ. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings Bull World Health Org 2003 81 277 85
9. Baltussen R Sylla M Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global and regional analysis Bull World Health Org 2004 82 338 45
10. Tan-Torres Edejer T Baltussen R Adam T et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis Geneva, Switzerland World Health Organization 2003
11. Gold MR Siegel JE Russell LB Weinstein MC. Cost-Effectiveness in Health and Medicine New York Oxford University Press 1996 425
12. American Joint Commission on Cancer. AJCC Cancer Staging Manual 6th ed New York Springer-Verlag 2002
13. Shibuya K Mathers CD Boschi-Pinto C Lopez AD Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 BMC Cancer 2002 2 37
14. Engel J Eckel R Kerr J et al. The process of metastasisation for breast cancer Eur J Cancer 2003 39 1794 806
15. Bland KI Menck HR Scott-Conner CE Morrow M Winchester DJ Winchester DP. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States Cancer 1998 83 1262 73
16. Sankaranarayanan R Black RJ Parkin DM. Cancer Survival in Developing Countries Lyon, France International Agency for Research on Cancer 1998 173
17. Murray CJL Lopez AD. Global Burden of Disease and Injury vol. 1 The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 Cambridge, MA Harvard School of Public Health 1996
18. Norum J. Breast cancer screening by mammography in Norway: is it cost-effective? Ann Oncol 1999 10 197 203
19. Launois R Reboul-Marty J Henry B Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine Pharmacoeconomics 1996 10 504 21
20. de Koning HJ van Ineveld BM van Oortmarssen GJ et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors Int J Cancer 1991 49 531 37
21. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, version 1, Breast Cancer [guideline] Jenkintown, PA National Comprehensive Cancer Network 2004 [updated March 19, 2004]. Available at ; accessed January 20, 2005
22. MD Anderson Cancer Center. Clinical Practice Guideline of the MDAnderson Cancer Center, Breast Cancer [guideline] Houston, TX MD Anderson Cancer Center 2004 [updated September 2, 2003]. Available at $FILE/Br%20Noninvasive %20Group%20V5.pdf; accessed January 20, 2005
23. Flobbe K van der Linden ES Kessels AG van Engelshoven JM. Diagnostic value of radiological breast imaging in a non-screening population Int J Cancer 2001 92 616 18
24. World Health Organization, Department of Essential Health Technologies. Essential Health Care Technology Package (EHTP) [Web page] Geneva, Switzerland World Health Organization 2005 Available at ; accessed January 20, 2005
25. Adam T Evans DB Murray CJ. Econometric estimation of country-specific hospital costs Cost Eff Resour Alloc 2003 1 3
26. Johns B Baltussen R. Accounting for the cost of scaling-up health interventions Health Econ 2004 13 1117 24
27. Johns B Baltussen R Hutubessy R. Programme costs in the economic evaluation of health interventions Cost Eff Resour Alloc 2003 1 1
28. Murray CJ Salomon JA. Expanding the WHO tuberculosis control strategy: rethinking the role of active case-finding Int J Tuberc Lung Dis 1998 2 S9 15
29. Garber AM Phelps CE. Economic foundations of cost-effectiveness analysis J Health Econ 1997 16 1 31
30. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life Geneva, Switzerland World Health Organization 2002
31. National Evaluation Team for Breast Cancer Screening in the Netherlands. Interim Report NETBMain Results Breast Cancer Screening Programme 2001 and 2002 in the Netherlands Rotterdam, The Netherlands Department of Public Health 2004
32. Schwartz LM Woloshin S Fowler FJ Jr. Welch HG. Enthusiasm for cancer screening in the United States JAMA 2004 291 71 78
33. Blamey RW. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group Eur J Surg Oncol 1998 24 464 76